[1]Patent:WO2013/40492,2013,A2.Locationinpatent:Page/Pagecolumn85
[1]Patent:US2013/273005,2013,A1
[2]Patent:US2018/79744,2018,A1
[3]Patent:WO2013/40492,2013,A2
[1]Patent:US2013/324496,2013,A1
Title: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Journal: Drugs 20170701
Title: Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901
Title: Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Journal: The New England journal of medicine 20150820
Title: Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
Journal: Hepatology (Baltimore, Md.) 20150601
Title: Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
Journal: Expert opinion on pharmacotherapy 20150401
Title: Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
Journal: Drugs 20150401
Title: Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
Journal: JAMA 20150301
Title: Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection.
Journal: World journal of virology 20150212
Title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Journal: Canadian journal of gastroenterology & hepatology 20150101
Title: Changing the face of hepatitis C management - the design and development of sofosbuvir.
Journal: Drug design, development and therapy 20150101
Title: Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.
Journal: Expert opinion on investigational drugs 20140401
Title: Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.
Journal: Journal of medicinal chemistry 20140313
Title: Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Journal: Antimicrobial agents and chemotherapy 20140201
Title: Side effects of alpha interferon in chronic hepatitis C.
Journal: Hepatology (Baltimore, Md.) 19970901
Title: Link JO, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46
Title: Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013 May;57(1):13-8.
Title: Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
